Nothing Special   »   [go: up one dir, main page]

Cignarella et al., 2018 - Google Patents

Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota

Cignarella et al., 2018

View HTML @Full View
Document ID
11089898572742206130
Author
Cignarella F
Cantoni C
Ghezzi L
Salter A
Dorsett Y
Chen L
Phillips D
Weinstock G
Fontana L
Cross A
Zhou Y
Piccio L
Publication year
Publication venue
Cell metabolism

External Links

Snippet

Multiple sclerosis (MS) is more common in western countries with diet being a potential contributing factor. Here we show that intermittent fasting (IF) ameliorated clinical course and pathology of the MS model, experimental autoimmune encephalomyelitis (EAE). IF led to …
Continue reading at www.cell.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Cignarella et al. Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota
Zhang et al. The gut microbiota: emerging evidence in autoimmune diseases
Tankou et al. A probiotic modulates the microbiome and immunity in multiple sclerosis
Verhaar et al. Gut microbiota composition is related to AD pathology
Jiang et al. Gut microbiota may play a significant role in the pathogenesis of Graves' disease
Schepici et al. The gut microbiota in multiple sclerosis: an overview of clinical trials
Mangalam et al. Human gut-derived commensal bacteria suppress CNS inflammatory and demyelinating disease
Horta-Baas et al. Intestinal dysbiosis and rheumatoid arthritis: a link between gut microbiota and the pathogenesis of rheumatoid arthritis
Marcial et al. Lactobacillus johnsonii N6. 2 modulates the host immune responses: a double-blind, randomized trial in healthy adults
Chen et al. Alterations in the gut microbiotas of children with food sensitization in early life
Hinks Mucosal‐associated invariant T cells in autoimmunity, immune‐mediated diseases and airways disease
Sofi et al. pH of drinking water influences the composition of gut microbiome and type 1 diabetes incidence
Demirci et al. Bacteroidetes and Firmicutes levels in gut microbiota and effects of hosts TLR2/TLR4 gene expression levels in adult type 1 diabetes patients in Istanbul, Turkey
Di Biase et al. Gut microbiota signatures and clinical manifestations in celiac disease children at onset: a pilot study
Olivares et al. Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease
Orivuori et al. High level of fecal calprotectin at age 2 months as a marker of intestinal inflammation predicts atopic dermatitis and asthma by age 6
Rook et al. Microbiota, immunoregulatory old friends and psychiatric disorders
Critchfield et al. The potential role of probiotics in the management of childhood autism spectrum disorders
Rigoni et al. Intestinal microbiota sustains inflammation and autoimmunity induced by hypomorphic RAG defects
Barletta et al. Probiotic VSL# 3‐induced TGF‐β ameliorates food allergy inflammation in a mouse model of peanut sensitization through the induction of regulatory T cells in the gut mucosa
Mowry et al. The dynamics of the gut microbiome in multiple sclerosis in relation to disease
Pandit et al. Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4
Sampath et al. Newly identified T cell subsets in mechanistic studies of food immunotherapy
Henschel et al. Modulation of the diet and gastrointestinal microbiota normalizes systemic inflammation and β-cell chemokine expression associated with autoimmune diabetes susceptibility
Huang et al. Early-life exposure to Clostridium leptum causes pulmonary immunosuppression